A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Status:
Terminated
Trial end date:
2020-06-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of single or multiple
doses of ALN-AAT02. The study will be conducted in 2 sequential phases in which Part A will
be a single-ascending dose (SAD) phase in healthy participants, and Part B will be a
multiple-ascending dose (MAD) phase in participants with ZZ type alpha-1 antitrypsin
deficiency (PiZZ) and biopsy-proven alpha-1 antitrypsin (AAT) deficiency-associated liver
disease.